Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Consistent Legal Evaluation And Regulation of Medical Products Act or the CLEAR Act This bill requires the Food and Drug Administration to regulate contrast agents for medical imaging devices, radioactive drugs, over-the-counter monograph drugs, and ophthalmic drug articles (i.e., eye droppers) as drugs rather than medical devices.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2023 · first_quarter · Health Issues
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Improvement Issues Medicare Physician Payment Issues Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act The Improving Seniors' Timely Access to Care Act S. 652, Safe Step Act The Ensuring Lasting Smiles Act Medicare Coverage for Low Vision Devices S. 4333, the CLEAR Act
Client expense: $443,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Medicare Physician Payment Reform Issues Medicare sequestration cuts Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act S. 4333, the CLEAR Act S. 4348, Food and Drug Administration Safety & Landmark Advancements (FDASLA) Act
Client expense: $406,636 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Compounded drugs H.R.7667-Food and Drug Amendments of 2022 S.4333-CLEAR Act S.4348-FDASLA Act of 2022
Client expense: $170,854 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act FY 2023 Omnibus Appropriations Bill
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES
2022 · fourth_quarter · Health Issues
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
Client expense: $75,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Medicare Physician Payment Reform Issues Medicare sequestration cuts Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act S. 4333, the CLEAR Act S. 4348, Food and Drug Administration Safety & Landmark Advancements (FDASLA) Act
Client expense: $295,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Health Issues
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Medical/Disease Research/Clinical Labs
Compounded drugs H.R.7667-Food and Drug Amendments of 2022 S.4333-CLEAR Act S.4348-FDASLA Act of 2022
Client expense: $194,452 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES
2022 · second_quarter · Medical/Disease Research/Clinical Labs
H.R.7667-Food and Drug Amendments of 2022 S.4333-CLEAR Act S.4348-FDASLA Act of 2022
Client expense: $154,186 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Implementation Issues Medicare Physician Payment Issues HR 315, Medicare Sequester COVID Moratorium Act Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Vision Services Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act Coronavirus Pandemic Relief Measures HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act S. 4333, the CLEAR Act S. 4348, Food and Drug Administration Safety & Landmark Advancements (FDASLA) Act
Client expense: $250,000 · Firm income: Not reported
2022 · second_quarter · Health Issues
Advocacy on HR 4479/S2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act, to fix policy packaging for radiopharmaceuticals; Advocacy with CMS on Beta Amyloid PET Medicare Coverage; Advocacy on HR 7667, the Food and Drug Administration Safety and Landmark Advancements Act of 2022 and S. 4333, the CLEAR Act, to allow FDA to continue regulating all imaging agents as drugs. Advocacy with Congress and FDA on H.R. 7084/S.3983 PATCH Act to seek improvements related to cybersecurity requirements of installed base devices; Advocacy on H.R. 7253, Clarifying Remanufacturing to Protect Patient Safety Act, to clarify the definition of remanufacturing and have education and enforcement of remanufacturers; Advocacy on HR 7667, the Food and Drug Administration Safety and Landmark Advancements Act of 2022 and provisions related to remanufacturing of medical devices and medical device cybersecurity; Advocacy on H.R. 2007 The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021, to promote research and use of noninvasive treatment alternatives for uterine fibroids; Advocacy on Digital Millennium Copyright Act (DMCA) Section 1201 and Right to Repair issues broadly; Advocacy on focused ultrasound technology; advocacy on medical device cybersecurity.
Client expense: $570,000 · Firm income: Not reported
2022 · second_quarter · Health Issues
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Indian/Native American Affairs
Implementation of S.47, Natural Resources Management Act (P.L.116-9). Issues related to FY20 Tribal Economic Development Bonds (S.4333/H.R.8066) Issues related to Alaska Native Claims Settlement Act income exclusion provisions.
Client expense: Not reported · Firm income: $30,000
Government targets: Army, Dept of (Corps of Engineers), Defense, Dept of (DOD), Energy, Dept of, Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, Treasury, Dept of
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE